Lyra Therapeutics, Inc. (LYRA) 10-Year Financial Performance & Capital Metrics

LYRA • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutLyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.Show more

Revenue $2M -1.5%
EBITDA -$96M -43.4%
Net Income -$93M -49.1%
EPS (Diluted) -1.43 -13.5%
Gross Margin 100%
EBITDA Margin -6250.13% -45.7%
Operating Margin -6280.83% -45.8%
Net Margin -6090.94% -51.4%
ROE -184.99% -151.1%
ROIC -145.47% -111.4%
Debt/Equity 2.97 +886.4%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗High debt to equity ratio of 3.0x
✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 3 (bottom 3%)
✗Shares diluted 30.7% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y75.25%

TTM-59.21%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM66.25%

EPS CAGR

10Y-

5Y-

3Y-

TTM-508.61%

ROCE

10Y Avg-73.67%

5Y Avg-77.01%

3Y Avg-85.24%

Latest-109.04%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.24M	0	0	285K	1.36M	1.56M	1.53M
Revenue Growth %	-	-1%	-	-	3.78%	0.14%	-0.02%
Cost of Goods Sold+	0	0	12.52M	29.69M	0	0	0
COGS % of Revenue	-	-	-	104.19%	-	-	-
Gross Profit+	1.24M	0	-12.52M	-29.41M	1.36M	1.56M	1.53M
Gross Margin %	1%	-	-	-103.19%	1%	1%	1%
Gross Profit Growth %	-	-1%	-	-1.35%	1.05%	0.14%	-0.02%
Operating Expenses+	8.5M	16.52M	9.69M	14.21M	57.67M	68.68M	97.88M
OpEx % of Revenue	6.84%	-	-	49.85%	42.31%	44.08%	63.81%
Selling, General & Admin	3.53M	4.49M	9.69M	14.21M	17.56M	19.06M	18.5M
SG&A % of Revenue	2.84%	-	-	49.85%	12.88%	12.23%	12.06%
Research & Development	4.97M	12.03M	12.52M	29.69M	38.8M	48.03M	43.77M
R&D % of Revenue	4%	-	-	104.19%	28.46%	30.83%	28.53%
Other Operating Expenses	0	-1	-12.52M	-29.69M	1.32M	1.59M	35.62M
Operating Income+	-7.26M	-16.52M	-22.21M	-43.62M	-56.31M	-67.12M	-96.35M
Operating Margin %	-5.84%	-	-	-153.04%	-41.31%	-43.08%	-62.81%
Operating Income Growth %	-	-1.28%	-0.34%	-0.96%	-0.29%	-0.19%	-0.44%
EBITDA+	-7.18M	-16.49M	-22.11M	-42.61M	-55.24M	-66.84M	-95.88M
EBITDA Margin %	-5.77%	-	-	-149.52%	-40.53%	-42.9%	-62.5%
EBITDA Growth %	-	-1.3%	-0.34%	-0.93%	-0.3%	-0.21%	-0.43%
D&A (Non-Cash Add-back)	82K	27K	95K	1M	1.07M	278K	471K
EBIT	-7.26M	-16.52M	-22.21M	-43.62M	-54.99M	-65.53M	-60.73M
Net Interest Income+	36K	213K	82K	102K	1.04M	4.5M	2.95M
Interest Income	36K	213K	82K	102K	1.04M	4.5M	2.95M
Interest Expense	0	0	0	0	0	0	0
Other Income/Expense	1.23M	213K	82K	102K	1.04M	4.5M	2.95M
Pretax Income+	-6.03M	-16.31M	-22.13M	-43.51M	-55.27M	-62.62M	-93.4M
Pretax Margin %	-4.85%	-	-	-152.68%	-40.55%	-40.19%	-60.88%
Income Tax+	0	0	0	0	13K	59K	39K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%
Net Income+	-6.03M	-16.31M	-22.13M	-43.51M	-55.28M	-62.68M	-93.44M
Net Margin %	-4.85%	-	-	-152.68%	-40.56%	-40.23%	-60.91%
Net Income Growth %	-	-1.7%	-0.36%	-0.97%	-0.27%	-0.13%	-0.49%
Net Income (Continuing)	-6.03M	-16.31M	-22.13M	-43.51M	-55.28M	-62.68M	-93.44M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-0.98	-62.50	-2.59	-3.35	-1.83	-1.26	-1.43
EPS Growth %	-	-62.78%	0.96%	-0.29%	0.45%	0.31%	-0.13%
EPS (Basic)	-0.98	-62.50	-2.59	-3.35	-1.83	-1.26	-1.43
Diluted Shares Outstanding	6.27M	8.18M	8.59M	12.99M	30.24M	49.8M	65.11M
Basic Shares Outstanding	6.27M	8.18M	8.55M	12.99M	30.24M	49.75M	65.11M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	24.93M	10.12M	75.92M	47.92M	100.83M	104.82M	43.02M
Cash & Short-Term Investments	23.89M	9.81M	74.59M	45.75M	97.89M	102.75M	40.58M
Cash Only	23.89M	9.81M	74.59M	45.75M	32.55M	22.35M	40.58M
Short-Term Investments	0	0	0	0	65.34M	80.4M	0
Accounts Receivable	167K	0	0	0	0	0	0
Days Sales Outstanding	49	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	2.94M	2.07M	2.45M
Total Non-Current Assets+	432K	4.84M	4.91M	6.95M	9.14M	37.78M	23.32M
Property, Plant & Equipment	103K	3.42M	4.47M	5.86M	4.47M	35.28M	21.33M
Fixed Asset Turnover	12.08x	-	-	0.05x	0.31x	0.04x	0.07x
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	329K	329K	0	0	0	1.39M	1.99M
Other Non-Current Assets	0	1.1M	447K	1.09M	4.67M	1.11M	0
Total Assets+	25.36M	14.96M	80.83M	54.87M	109.97M	142.6M	66.35M
Asset Turnover	0.05x	-	-	0.01x	0.01x	0.01x	0.02x
Asset Growth %	-	-0.41%	4.4%	-0.32%	1%	0.3%	-0.53%
Total Current Liabilities+	1.96M	5.21M	4.88M	18.25M	14.47M	19.6M	12.63M
Accounts Payable	631K	1.07M	922K	3.13M	2.62M	3.13M	1.18M
Days Payables Outstanding	-	-	26.88	38.41	-	-	-
Short-Term Debt	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	1000K	0	1000K	1000K	1000K	398K
Other Current Liabilities	845K	-3.02M	149K	633K	659K	1.23M	6.93M
Current Ratio	12.72x	1.94x	15.54x	2.63x	6.97x	5.35x	3.41x
Quick Ratio	12.72x	1.94x	15.54x	2.63x	6.97x	5.35x	3.41x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	130.47M	2.43M	1.45M	2.31M	14.74M	33.58M	42.12M
Long-Term Debt	0	0	0	0	0	0	0
Capital Lease Obligations	0	2.43M	1.45M	379K	667K	21.45M	30.26M
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	130.47M	0	0	0	0	0	0
Total Liabilities	132.43M	7.63M	6.34M	20.55M	29.21M	53.18M	54.75M
Total Debt+	0	3.33M	2.44M	1.45M	4.18M	26.88M	34.38M
Net Debt	-23.89M	-6.48M	-72.15M	-44.29M	-28.37M	4.53M	-6.2M
Debt / Equity	-	0.45x	0.03x	0.04x	0.05x	0.30x	2.97x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-
Total Equity+	-107.07M	7.33M	74.49M	34.32M	80.75M	89.42M	11.59M
Equity Growth %	-	1.07%	9.17%	-0.54%	1.35%	0.11%	-0.87%
Book Value per Share	-17.09	0.90	8.67	2.64	2.67	1.80	0.18
Total Shareholders' Equity	-107.07M	7.33M	74.49M	34.32M	80.75M	89.42M	11.59M
Common Stock	6K	6K	13K	13K	32K	57K	65K
Retained Earnings	-111.45M	-127.76M	-149.88M	-193.4M	-248.68M	-311.36M	-404.79M
Treasury Stock	-4.37M	0	0	0	0	0	0
Accumulated OCI	-2.8M	0	0	0	10K	33K	0
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-6.64M	-13.75M	-21.14M	-25.82M	-43.38M	-63.3M	-70.01M
Operating CF Margin %	-5.34%	-	-	-90.6%	-31.83%	-40.63%	-45.64%
Operating CF Growth %	-	-1.07%	-0.54%	-0.22%	-0.68%	-0.46%	-0.11%
Net Income	-6.03M	-16.31M	-22.13M	-43.51M	-55.28M	-62.68M	-93.44M
Depreciation & Amortization	82K	27K	95K	1M	1.07M	278K	471K
Stock-Based Compensation	406K	0	1.81M	2.77M	5.45M	5.89M	6.72M
Deferred Taxes	0	0	0	-2.42M	0	0	0
Other Non-Cash Items	-1.18M	411K	-45K	2.42M	824K	-1.9M	22.58M
Working Capital Changes	79K	2.11M	-879K	13.92M	4.55M	-4.88M	-6.35M
Change in Receivables	164K	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	134K	-205K	345K	2.35M	-2.41M	450K	-1.89M
Cash from Investing+	-37K	-211K	-1.77M	-3.38M	-65.01M	-12.58M	80.31M
Capital Expenditures	-37K	-211K	-1.77M	-3.38M	-164K	-1.05M	-2.34M
CapEx % of Revenue	0.03%	-	-	11.88%	0.12%	0.67%	1.52%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0
Cash from Financing+	29.21M	-115K	87.7M	359K	96.26M	65.69M	8.53M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	28.71M	-226K	-2.58M	-245K	-4.24M	-3.55M	-287K
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-6.68M	-13.96M	-22.92M	-29.2M	-43.55M	-64.35M	-72.35M
FCF Margin %	-5.37%	-	-	-102.47%	-31.95%	-41.3%	-47.16%
FCF Growth %	-	-1.09%	-0.64%	-0.27%	-0.49%	-0.48%	-0.12%
FCF per Share	-1.07	-1.71	-2.67	-2.25	-1.44	-1.29	-1.11
FCF Conversion (FCF/Net Income)	1.10x	0.84x	0.96x	0.59x	0.78x	1.01x	0.75x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-222.52%	-54.09%	-79.98%	-96.08%	-73.67%	-184.99%
Return on Invested Capital (ROIC)	-	-	-1046.28%	-	-199.18%	-68.8%	-145.47%
Gross Margin	100%	-	-	-10318.95%	100%	100%	100%
Net Margin	-484.65%	-	-	-15267.72%	-4055.61%	-4023.11%	-6090.94%
Debt / Equity	-	0.45x	0.03x	0.04x	0.05x	0.30x	2.97x
FCF Conversion	1.10x	0.84x	0.96x	0.59x	0.78x	1.01x	0.75x
Revenue Growth	-	-100%	-	-	378.25%	14.31%	-1.54%

Frequently Asked Questions

Growth & Financials

Lyra Therapeutics, Inc. (LYRA) reported $0.6M in revenue for fiscal year 2024. This represents a 52% decrease from $1.2M in 2018.

Lyra Therapeutics, Inc. (LYRA) saw revenue decline by 1.5% over the past year.

Lyra Therapeutics, Inc. (LYRA) reported a net loss of $32.9M for fiscal year 2024.

Dividend & Returns

Lyra Therapeutics, Inc. (LYRA) has a return on equity (ROE) of -185.0%. Negative ROE indicates the company is unprofitable.

Lyra Therapeutics, Inc. (LYRA) had negative free cash flow of $34.1M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Lyra Therapeutics, Inc. (LYRA) 10-Year Financial Performance & Capital Metrics

LYRA • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $2M -1.5%
EBITDA -$96M -43.4%
Net Income -$93M -49.1%
EPS (Diluted) -1.43 -13.5%
Gross Margin 100%
EBITDA Margin -6250.13% -45.7%
Operating Margin -6280.83% -45.8%
Net Margin -6090.94% -51.4%
ROE -184.99% -151.1%
ROIC -145.47% -111.4%
Debt/Equity 2.97 +886.4%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗High debt to equity ratio of 3.0x
✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 3 (bottom 3%)
✗Shares diluted 30.7% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y75.25%

TTM-59.21%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM66.25%

EPS CAGR

10Y-

5Y-

3Y-

TTM-508.61%

ROCE

10Y Avg-73.67%

5Y Avg-77.01%

3Y Avg-85.24%

Latest-109.04%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.24M	0	0	285K	1.36M	1.56M	1.53M
Revenue Growth %	-	-1%	-	-	3.78%	0.14%	-0.02%
Cost of Goods Sold+	0	0	12.52M	29.69M	0	0	0
COGS % of Revenue	-	-	-	104.19%	-	-	-
Gross Profit+	1.24M	0	-12.52M	-29.41M	1.36M	1.56M	1.53M
Gross Margin %	1%	-	-	-103.19%	1%	1%	1%
Gross Profit Growth %	-	-1%	-	-1.35%	1.05%	0.14%	-0.02%
Operating Expenses+	8.5M	16.52M	9.69M	14.21M	57.67M	68.68M	97.88M
OpEx % of Revenue	6.84%	-	-	49.85%	42.31%	44.08%	63.81%
Selling, General & Admin	3.53M	4.49M	9.69M	14.21M	17.56M	19.06M	18.5M
SG&A % of Revenue	2.84%	-	-	49.85%	12.88%	12.23%	12.06%
Research & Development	4.97M	12.03M	12.52M	29.69M	38.8M	48.03M	43.77M
R&D % of Revenue	4%	-	-	104.19%	28.46%	30.83%	28.53%
Other Operating Expenses	0	-1	-12.52M	-29.69M	1.32M	1.59M	35.62M
Operating Income+	-7.26M	-16.52M	-22.21M	-43.62M	-56.31M	-67.12M	-96.35M
Operating Margin %	-5.84%	-	-	-153.04%	-41.31%	-43.08%	-62.81%
Operating Income Growth %	-	-1.28%	-0.34%	-0.96%	-0.29%	-0.19%	-0.44%
EBITDA+	-7.18M	-16.49M	-22.11M	-42.61M	-55.24M	-66.84M	-95.88M
EBITDA Margin %	-5.77%	-	-	-149.52%	-40.53%	-42.9%	-62.5%
EBITDA Growth %	-	-1.3%	-0.34%	-0.93%	-0.3%	-0.21%	-0.43%
D&A (Non-Cash Add-back)	82K	27K	95K	1M	1.07M	278K	471K
EBIT	-7.26M	-16.52M	-22.21M	-43.62M	-54.99M	-65.53M	-60.73M
Net Interest Income+	36K	213K	82K	102K	1.04M	4.5M	2.95M
Interest Income	36K	213K	82K	102K	1.04M	4.5M	2.95M
Interest Expense	0	0	0	0	0	0	0
Other Income/Expense	1.23M	213K	82K	102K	1.04M	4.5M	2.95M
Pretax Income+	-6.03M	-16.31M	-22.13M	-43.51M	-55.27M	-62.62M	-93.4M
Pretax Margin %	-4.85%	-	-	-152.68%	-40.55%	-40.19%	-60.88%
Income Tax+	0	0	0	0	13K	59K	39K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%
Net Income+	-6.03M	-16.31M	-22.13M	-43.51M	-55.28M	-62.68M	-93.44M
Net Margin %	-4.85%	-	-	-152.68%	-40.56%	-40.23%	-60.91%
Net Income Growth %	-	-1.7%	-0.36%	-0.97%	-0.27%	-0.13%	-0.49%
Net Income (Continuing)	-6.03M	-16.31M	-22.13M	-43.51M	-55.28M	-62.68M	-93.44M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-0.98	-62.50	-2.59	-3.35	-1.83	-1.26	-1.43
EPS Growth %	-	-62.78%	0.96%	-0.29%	0.45%	0.31%	-0.13%
EPS (Basic)	-0.98	-62.50	-2.59	-3.35	-1.83	-1.26	-1.43
Diluted Shares Outstanding	6.27M	8.18M	8.59M	12.99M	30.24M	49.8M	65.11M
Basic Shares Outstanding	6.27M	8.18M	8.55M	12.99M	30.24M	49.75M	65.11M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	24.93M	10.12M	75.92M	47.92M	100.83M	104.82M	43.02M
Cash & Short-Term Investments	23.89M	9.81M	74.59M	45.75M	97.89M	102.75M	40.58M
Cash Only	23.89M	9.81M	74.59M	45.75M	32.55M	22.35M	40.58M
Short-Term Investments	0	0	0	0	65.34M	80.4M	0
Accounts Receivable	167K	0	0	0	0	0	0
Days Sales Outstanding	49	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	2.94M	2.07M	2.45M
Total Non-Current Assets+	432K	4.84M	4.91M	6.95M	9.14M	37.78M	23.32M
Property, Plant & Equipment	103K	3.42M	4.47M	5.86M	4.47M	35.28M	21.33M
Fixed Asset Turnover	12.08x	-	-	0.05x	0.31x	0.04x	0.07x
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	329K	329K	0	0	0	1.39M	1.99M
Other Non-Current Assets	0	1.1M	447K	1.09M	4.67M	1.11M	0
Total Assets+	25.36M	14.96M	80.83M	54.87M	109.97M	142.6M	66.35M
Asset Turnover	0.05x	-	-	0.01x	0.01x	0.01x	0.02x
Asset Growth %	-	-0.41%	4.4%	-0.32%	1%	0.3%	-0.53%
Total Current Liabilities+	1.96M	5.21M	4.88M	18.25M	14.47M	19.6M	12.63M
Accounts Payable	631K	1.07M	922K	3.13M	2.62M	3.13M	1.18M
Days Payables Outstanding	-	-	26.88	38.41	-	-	-
Short-Term Debt	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	1000K	0	1000K	1000K	1000K	398K
Other Current Liabilities	845K	-3.02M	149K	633K	659K	1.23M	6.93M
Current Ratio	12.72x	1.94x	15.54x	2.63x	6.97x	5.35x	3.41x
Quick Ratio	12.72x	1.94x	15.54x	2.63x	6.97x	5.35x	3.41x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	130.47M	2.43M	1.45M	2.31M	14.74M	33.58M	42.12M
Long-Term Debt	0	0	0	0	0	0	0
Capital Lease Obligations	0	2.43M	1.45M	379K	667K	21.45M	30.26M
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	130.47M	0	0	0	0	0	0
Total Liabilities	132.43M	7.63M	6.34M	20.55M	29.21M	53.18M	54.75M
Total Debt+	0	3.33M	2.44M	1.45M	4.18M	26.88M	34.38M
Net Debt	-23.89M	-6.48M	-72.15M	-44.29M	-28.37M	4.53M	-6.2M
Debt / Equity	-	0.45x	0.03x	0.04x	0.05x	0.30x	2.97x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-
Total Equity+	-107.07M	7.33M	74.49M	34.32M	80.75M	89.42M	11.59M
Equity Growth %	-	1.07%	9.17%	-0.54%	1.35%	0.11%	-0.87%
Book Value per Share	-17.09	0.90	8.67	2.64	2.67	1.80	0.18
Total Shareholders' Equity	-107.07M	7.33M	74.49M	34.32M	80.75M	89.42M	11.59M
Common Stock	6K	6K	13K	13K	32K	57K	65K
Retained Earnings	-111.45M	-127.76M	-149.88M	-193.4M	-248.68M	-311.36M	-404.79M
Treasury Stock	-4.37M	0	0	0	0	0	0
Accumulated OCI	-2.8M	0	0	0	10K	33K	0
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-6.64M	-13.75M	-21.14M	-25.82M	-43.38M	-63.3M	-70.01M
Operating CF Margin %	-5.34%	-	-	-90.6%	-31.83%	-40.63%	-45.64%
Operating CF Growth %	-	-1.07%	-0.54%	-0.22%	-0.68%	-0.46%	-0.11%
Net Income	-6.03M	-16.31M	-22.13M	-43.51M	-55.28M	-62.68M	-93.44M
Depreciation & Amortization	82K	27K	95K	1M	1.07M	278K	471K
Stock-Based Compensation	406K	0	1.81M	2.77M	5.45M	5.89M	6.72M
Deferred Taxes	0	0	0	-2.42M	0	0	0
Other Non-Cash Items	-1.18M	411K	-45K	2.42M	824K	-1.9M	22.58M
Working Capital Changes	79K	2.11M	-879K	13.92M	4.55M	-4.88M	-6.35M
Change in Receivables	164K	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	134K	-205K	345K	2.35M	-2.41M	450K	-1.89M
Cash from Investing+	-37K	-211K	-1.77M	-3.38M	-65.01M	-12.58M	80.31M
Capital Expenditures	-37K	-211K	-1.77M	-3.38M	-164K	-1.05M	-2.34M
CapEx % of Revenue	0.03%	-	-	11.88%	0.12%	0.67%	1.52%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0
Cash from Financing+	29.21M	-115K	87.7M	359K	96.26M	65.69M	8.53M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	28.71M	-226K	-2.58M	-245K	-4.24M	-3.55M	-287K
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-6.68M	-13.96M	-22.92M	-29.2M	-43.55M	-64.35M	-72.35M
FCF Margin %	-5.37%	-	-	-102.47%	-31.95%	-41.3%	-47.16%
FCF Growth %	-	-1.09%	-0.64%	-0.27%	-0.49%	-0.48%	-0.12%
FCF per Share	-1.07	-1.71	-2.67	-2.25	-1.44	-1.29	-1.11
FCF Conversion (FCF/Net Income)	1.10x	0.84x	0.96x	0.59x	0.78x	1.01x	0.75x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-222.52%	-54.09%	-79.98%	-96.08%	-73.67%	-184.99%
Return on Invested Capital (ROIC)	-	-	-1046.28%	-	-199.18%	-68.8%	-145.47%
Gross Margin	100%	-	-	-10318.95%	100%	100%	100%
Net Margin	-484.65%	-	-	-15267.72%	-4055.61%	-4023.11%	-6090.94%
Debt / Equity	-	0.45x	0.03x	0.04x	0.05x	0.30x	2.97x
FCF Conversion	1.10x	0.84x	0.96x	0.59x	0.78x	1.01x	0.75x
Revenue Growth	-	-100%	-	-	378.25%	14.31%	-1.54%

Frequently Asked Questions

Growth & Financials

Lyra Therapeutics, Inc. (LYRA) reported $0.6M in revenue for fiscal year 2024. This represents a 52% decrease from $1.2M in 2018.

Lyra Therapeutics, Inc. (LYRA) saw revenue decline by 1.5% over the past year.

Lyra Therapeutics, Inc. (LYRA) reported a net loss of $32.9M for fiscal year 2024.

Dividend & Returns

Lyra Therapeutics, Inc. (LYRA) has a return on equity (ROE) of -185.0%. Negative ROE indicates the company is unprofitable.

Lyra Therapeutics, Inc. (LYRA) had negative free cash flow of $34.1M in fiscal year 2024, likely due to heavy capital investments.